Armata Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2005-01-01
- Employees
- 66
- Market Cap
- $87M
- Website
- http://www.armatapharma.com
- Introduction
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
- Conditions
- Lung InfectionNon-cystic Fibrosis BronchiectasisPseudomonas Aeruginosa
- Interventions
- Other: PlaceboBiological: AP-PA02
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05616221
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸University of Pennslyvania, Philadelphia, Pennsylvania, United States
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
- Conditions
- BacteremiaBacteremia StaphStaphylococcus AureusBacteremia Due to Staphylococcus AureusStaphylococcus Aureus Bacteremia
- Interventions
- Biological: AP-SA02Other: Placebo
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05184764
- Locations
- 🇺🇸
Banner University Medical Center, Tucson, Arizona, United States
🇺🇸University of California, San Diego (UCSD) - Medical Center, La Jolla, California, United States
🇺🇸University of Southern California Keck School of Medicine, Los Angeles, California, United States
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
- Conditions
- PseudomonasCystic FibrosisPseudomonas AeruginosaLung InfectionLung Infection Pseudomonal
- Interventions
- Biological: AP-PA02Other: Placebo
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04596319
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Registration Number
- NCT03395743
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Registration Number
- NCT03395769
A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects
- Conditions
- Dental Caries
- Interventions
- Drug: C16G2Drug: Placebo
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03196219
- Locations
- 🇺🇸
John F. Pittaway, DMD, Kalispell, Montana, United States
A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application
- Conditions
- Dental Caries
- Interventions
- Other: Placebo StripDrug: C16G2 Strip
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03052842
- Locations
- 🇺🇸
Jacqueline Kleven, DDS, Bedford, Texas, United States
🇺🇸John F. Pittaway, DMD, Kalispell, Montana, United States
🇺🇸Anthony Henegar, DDS, PA, Irving, Texas, United States
A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects
- Conditions
- Dental Caries
- Interventions
- Drug: C16G2 VarnishDrug: Placebo Varnish
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03004365
- Locations
- 🇺🇸
John F. Pittaway, DMD, Kalispell, Montana, United States
🇺🇸Anthony Henegar, DDS, PA, Irving, Texas, United States
🇺🇸Jacqueline Kleven, DDS, Bedford, Texas, United States
Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- Biological: AB-SA01 (10^9 PFU per phage)Biological: AB-SA01 (10^8 PFU per phage)Biological: Placebo (for Cohort 10^9)Biological: Placebo (for Cohort 10^8)
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02757755
- Locations
- 🇺🇸
Clinical Trials Center, WRAIR, Silver Spring, Maryland, United States
Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects
- Conditions
- Dental Caries
- Interventions
- Drug: C16G2 GelOther: Placebo
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT02594254
- Locations
- 🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇺🇸Tufts University, Boston, Massachusetts, United States
🇺🇸Indiana University School of Dentistry, Indianapolis, Indiana, United States